Lymphoma Clinical Trials in Tennessee

Showing 21-40 of 653 trials

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

NCT06678659

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.

UnresectableLocally AdvancedMetastatic Cancers+1 more

Recursion Pharmaceuticals Inc.170 participantsStarted Nov 2024

Duarte, California, United States • Cleveland, Ohio, United States • Nashville, Tennessee, United States +3 more locations

Active Not RecruitingPhase 129 miles

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT05424822

The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\[s\]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D(s) in Part B (Cohort Expansion).

Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Janssen Research & Development, LLC167 participantsStarted Aug 2022

Duarte, California, United States • New York, New York, United States • New York, New York, United States +26 more locations

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphoma Trials in Other Cities

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

DS-3201b in Participants With Lymphomas

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

Other Conditions in Tennessee